MedTrace Logo

Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer

NCT00842582 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2016-11-02

No results posted yet for this study

Summary

This is a clinical trial for women with newly diagnosed ovarian cancer. The purpose of this study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to carboplatin and paclitaxel will change the genetic material of the tumor so that the chemotherapy drugs work better.

The study will also determine what the maximum tolerated dose of azacitidine that may be safely used in combination with carboplatin and paclitaxel.

Conditions

Interventions

DRUG

Azacitidine

Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.

DRUG

Azacitidine

Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.

DRUG

Azacitidine

Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Loyola University

    lead OTHER

Principal Investigators

  • Laura Horvath, MD · Loyola University Cardinal Bernadin Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842582 on ClinicalTrials.gov